LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole.

    Madhusoodanan, Subramanian / Shah, Payal

    Clinical interventions in aging

    2008  Volume 3, Issue 3, Page(s) 491–501

    Abstract: Psychosis of Alzheimer's disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of ... ...

    Abstract Psychosis of Alzheimer's disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in view of the modest efficacy and relative safety until FDA warnings were issued in 2005 and meta-analytic studies showed no significant difference to placebo. The FDA warnings on the cardiac, metabolic, cerebrovascular, and mortality risks have caused serious concerns for the use of atypical antipsychotic agents in elderly patients with dementia. Only a few studies have evaluated prospectively the effects of aripiprazole in psychosis associated with AD. These studies show improvement in the symptoms of psychosis associated with AD with aripiprazole. The safety and tolerability profile of aripiprazole suggests a low potential for negative impact on dementia and overall patient health. Further studies comparing the efficacy and tolerability of aripiprazole vs other atypical antipsychotics in dementia are needed.
    MeSH term(s) Aged ; Aged, 80 and over ; Alzheimer Disease/complications ; Antipsychotic Agents/therapeutic use ; Aripiprazole ; Humans ; Hyperglycemia ; Piperazines/therapeutic use ; Psychotic Disorders/complications ; Psychotic Disorders/drug therapy ; Quinolones/therapeutic use ; Treatment Outcome
    Chemical Substances Antipsychotic Agents ; Piperazines ; Quinolones ; Aripiprazole (82VFR53I78)
    Language English
    Publishing date 2008-10-01
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2364924-0
    ISSN 1176-9092
    ISSN 1176-9092
    DOI 10.2147/cia.s3351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Management of psychosis in patients with Alzheimer’s disease

    Subramanian Madhusoodanan / Payal Shah

    Clinical Interventions in Aging, Vol 2008, Iss Issue 3, Pp 491-

    focus on aripiprazole

    2008  Volume 501

    Abstract: Subramanian Madhusoodanan1, Payal Shah21St John’s Episcopal Hospital Far Rockaway, NY 11691, SUNY ...

    Abstract Subramanian Madhusoodanan1, Payal Shah21St John’s Episcopal Hospital Far Rockaway, NY 11691, SUNY, Brooklyn NY, USA. 2SUNY Health Science Center, Brooklyn, NYAbstract: Psychosis of Alzheimer’s disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in view of the modest efficacy and relative safety until FDA warnings were issued in 2005 and meta-analytic studies showed no significant difference to placebo. The FDA warnings on the cardiac, metabolic, cerebrovascular, and mortality risks have caused serious concerns for the use of atypical antipsychotic agents in elderly patients with dementia. Only a few studies have evaluated prospectively the effects of aripiprazole in psychosis associated with AD. These studies show improvement in the symptoms of psychosis associated with AD with aripiprazole. The safety and tolerability profile of aripiprazole suggests a low potential for negative impact on dementia and overall patient health. Further studies comparing the efficacy and tolerability of aripiprazole vs other atypical antipsychotics in dementia are needed.Keywords: treatment, Alzheimer’s dementia, psychosis, aripiprazole
    Keywords Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Geriatrics ; RC952-954.6
    Subject code 150
    Language English
    Publishing date 2008-10-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Tardive dyskinesia: legal issues and consent.

    Gupta, Sanjay / Frank, Bradford / Madhusoodanan, Subramaniam

    Psychiatric annals

    2003  Volume 32, Issue 4, Page(s) 245–248

    MeSH term(s) Antipsychotic Agents/adverse effects ; Consent Forms/legislation & jurisprudence ; Dyskinesia, Drug-Induced ; Humans ; Informed Consent/legislation & jurisprudence ; Informed Consent/standards ; Liability, Legal ; Mentally Ill Persons ; Psychiatry/legislation & jurisprudence ; Psychiatry/standards ; Risk ; United States
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2003-05-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 222181-0
    ISSN 0048-5713
    ISSN 0048-5713
    DOI 10.3928/0048-5713-20020401-09
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top